The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure ...
Sneezing in the morning, a runny nose or coughing often goes unnoticed as minor ailments in kids. However, these harmless ...
Persistent radiologic abnormalities after COVID-19 were common 28-60 days post-discharge, often showing improvement but remaining linked to long-term health quality, highlighting a population ...
Visible on chest CT scans, post-COVID-19 residual lung abnormalities, which affect up to 50% of patients who have had an infection requiring hospitalization, may be associated with persistent or ...
Two-thirds of people with post-COVID-19 syndrome have persistent, objective symptoms – including reduced physical exercise capacity and reduced cognitive test performances – for a year or more, with ...
Researchers found that workers in remote jobs spent more time alone after the COVID-19 pandemic and experienced greater ...
Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results